Keytruda and Linagliptin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Keytruda (pembrolizumab) and Linagliptin (linagliptin). Common drug interactions include decreased appetite among females and interstitial lung disease among males.

The phase IV clinical study analyzes what interactions people have when they take Keytruda and Linagliptin. It is created by eHealthMe based on reports of 42 people who take the same drugs from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Linagliptin?

Linagliptin has active ingredients of linagliptin. eHealthMe is studying from 8,112 Linagliptin users. Check the latest studies of Linagliptin.

On Jul, 05, 2026

42 people who take Keytruda and Linagliptin together, and have interactions are studied.

Keytruda and Linagliptin drug interactions.

What are the common drug interactions of Keytruda and Linagliptin, by gender? *:

female:

Decreased appetite
Drug eruption (adverse drug reaction of the skin)
Alopecia (absence of hair from areas of the body)
Amylase increased
Constipation
Dehydration (dryness resulting from the removal of water)
Diarrhoea
Glucose tolerance impaired (blood glucose is raised beyond normal levels, but not high enough to warrant a diabetes diagnosis)
Hepatic cyst
Hepatic lesion

male:

Interstitial lung disease
Rash
Hypertension (high blood pressure)
Malaise (a feeling of general discomfort or uneasiness)
Oropharyngeal discomfort (pain or irritation of oropharynx)
Pruritus (severe itching of the skin)
Skin disorder (skin disease)
Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)
Dysphonia (speech disorder attributable to a disorder of phonation)
Renal impairment (severely reduced kidney function)

What are the common drug interactions of Keytruda and Linagliptin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Abdominal pain
Dehydration (dryness resulting from the removal of water)
Diarrhoea
Haemoglobinaemia (excess of haemoglobin in the blood plasma)
Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)
Pancreatic disorder
Renal failure (kidney dysfunction)
Vomiting

60+:

Interstitial lung disease
Rash
Malaise (a feeling of general discomfort or uneasiness)
Oropharyngeal discomfort (pain or irritation of oropharynx)
Pruritus (severe itching of the skin)
Renal impairment (severely reduced kidney function)
Skin disorder (skin disease)
Diarrhoea
Drug eruption (adverse drug reaction of the skin)
Drug-induced liver injury (diseases of the liver that are caused by physician-prescribed medications)

What are the existing conditions these people have? *

Type 2 Diabetes: 7 people, 16.67%
High Blood Pressure: 7 people, 16.67%
Diabetes: 7 people, 16.67%
Ureteric Cancer: 5 people, 11.90%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 5 people, 11.90%
Lung Cancer - Non-Small Cell (lung cancer): 4 people, 9.52%
Pain: 3 people, 7.14%
Malignant Neoplasm Progression (cancer tumour came back): 3 people, 7.14%
Itching: 3 people, 7.14%
Groin Pain: 3 people, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and Linagliptin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously